ADVEON Trademark

Trademark Overview


On Thursday, April 16, 2015, a trademark application was filed for ADVEON with the United States Patent and Trademark Office. The USPTO has given the ADVEON trademark a serial number of 86600429. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Wednesday, November 4, 2015. This trademark is owned by Warner Chilcott Company, LLC. The ADVEON trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals...
adveon

General Information


Serial Number86600429
Word MarkADVEON
Filing DateThursday, April 16, 2015
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateWednesday, November 4, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 15, 2015

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungals; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations for use as a neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateWednesday, November 4, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Party Type21 - New Owner After Publication
Legal Entity Type77 - NOT AVAILABLE
AddressCOOLOCK, DUBLIN 17
IE

Party NameWarner Chilcott Company, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressFajardo 00738
PR

Party NameWarner Chilcott Company, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressFajardo 00738
PR

Trademark Events


Event DateEvent Description
Wednesday, February 19, 2020ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, June 21, 2017AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, November 4, 2015ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Wednesday, November 4, 2015ABANDONMENT - AFTER PUBLICATION
Monday, November 2, 2015TEAS EXPRESS ABANDONMENT RECEIVED
Monday, October 12, 2015EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, September 15, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 15, 2015PUBLISHED FOR OPPOSITION
Wednesday, August 26, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 13, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, August 7, 2015ASSIGNED TO LIE
Monday, July 27, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 27, 2015EXAMINER'S AMENDMENT ENTERED
Monday, July 27, 2015NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, July 27, 2015EXAMINERS AMENDMENT E-MAILED
Monday, July 27, 2015EXAMINERS AMENDMENT -WRITTEN
Friday, July 24, 2015ASSIGNED TO EXAMINER
Friday, April 24, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, April 20, 2015NEW APPLICATION ENTERED IN TRAM